Kunal Ramtri brings over two decades of leadership experience across commodity trading, refining, and large-scale business ...

Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...

Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.